INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 400 | $580.29 | 543,348 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,500 | $579.53 | 543,748 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 268 | $578.73 | 545,248 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,996 | $577.58 | 545,516 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 617
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 8,024 | $473.39 | 546,694 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 865 | $576.48 | 547,512 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,441 | $575.64 | 548,377 |
| Dec 08, 2009 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 187,500 | $8.77 | 548,751 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 19,982 | $569.52 | 549,258 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,693 | $574.55 | 550,818 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.